When pharma innovators look to derisk their sources of API supply, one name often comes up: Sai Life Sciences. As India’s leading, pure-play CRDMO we serve 18 of the top 25 largest innovator pharma companies. We have been involved in > 10% of all small molecule NCEs approved by USFDA in the last 4 years. Having tech transferred 16 late-stage projects to our sites from China, Europe and Asia in the last 3 years, we’re becoming a partner of choice in the geographic risk-mitigation strategies of pharma innovators.
Sai Life Sciences is India’s fastest growing CRDMO. For over 25 years, we have been a trusted partner in bringing new medicines to life, fast. We build lasting partnerships with our clients through collaboration. Taking a nimble and creative approach, we deliver high-quality, cost-effective solutions for our biotech and pharma partners to accelerate the time to market.
We are dedicated to fostering long-term partnerships that deliver mutual value. By integrating sustainability into every aspect of our operations, we ensure that our value creation is resilient, responsible, and aligned with the needs of our stakeholders.
Our quality system is designed to meet the most stringent global regulatory standards. This enables us deliver products that consistently meet the expectations of the markets we serve, particularly US, EU and Japan.
A culture of excellence can only be built through sustained focus on strengthening the systems and capabilities that drive performance. At Sai, we have a sustained focus on enhancing automation, data systems, training, organizational processes, and shop-floor transformation to enable long-term excellence.